Summit Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$455K Sell
18,916
-153
-0.8% -$4K 0.06% 118
2026
Q1
$535K Sell
19,069
-270
-1% -$7.19K 0.07% 104
2025
Q4
$482K Sell
19,339
-4,476
-19% -$113K 0.07% 107
2025
Q3
$607K Sell
23,815
-300
-1% -$7.41K 0.09% 96
2025
Q2
$585K Buy
24,115
+848
+4% +$19.8K 0.1% 96
2025
Q1
$590K Hold
23,267
0.1% 92
2024
Q4
$617K Buy
23,267
+839
+4% +$22.8K 0.11% 89
2024
Q3
$649K Buy
22,428
+1,063
+5% +$31K 0.12% 83
2024
Q2
$598K Sell
21,365
-574
-3% -$15.8K 0.12% 83
2024
Q1
$609K Sell
21,939
-24
-0.1% -$666 0.13% 82
2023
Q4
$632K Sell
21,963
-185
-0.8% -$5.59K 0.15% 70
2023
Q3
$735K Buy
22,148
+151
+0.7% +$5.34K 0.2% 58
2023
Q2
$807K Sell
21,997
-310
-1% -$12.1K 0.21% 56
2023
Q1
$910K Buy
22,307
+141
+0.6% +$6.09K 0.25% 51
2022
Q4
$1.14M Sell
22,166
-5
-0% -$240 0.33% 40
2022
Q3
$970K Sell
22,171
-2,697
-11% -$131K 0.31% 45
2022
Q2
$1.3M Sell
24,868
-345
-1% -$17.6K 0.4% 34
2022
Q1
$1.3M Buy
25,213
+875
+4% +$45.4K 0.37% 40
2021
Q4
$1.44M Buy
24,338
+1,595
+7% +$79K 0.41% 36
2021
Q3
$978K Buy
22,743
+457
+2% +$20.2K 0.31% 48
2021
Q2
$873K Buy
22,286
+1,093
+5% +$42.5K 0.27% 53
2021
Q1
$768K Sell
21,193
-79
-0.4% -$2.81K 0.26% 57
2020
Q4
$783K Sell
21,272
-1,126
-5% -$41.3K 0.29% 52
2020
Q3
$780K Buy
22,398
+594
+3% +$20.8K 0.32% 43
2020
Q2
$676K Buy
21,804
+399
+2% +$13.6K 0.31% 47
2020
Q1
$663K Buy
21,405
+1,081
+5% +$36.8K 0.36% 42
2019
Q4
$756K Sell
20,324
-661
-3% -$23.5K 0.32% 46
2019
Q3
$715K Buy
20,985
+52
+0.2% +$1.89K 0.33% 43
2019
Q2
$860K Buy
20,933
+74
+0.4% +$2.94K 0.41% 36
2019
Q1
$840K Sell
20,859
-1,196
-5% -$47.9K 0.41% 36
2018
Q4
$913K Buy
22,055
+220
+1% +$9.13K 0.52% 30
2018
Q3
$913K Buy
21,835
+1,094
+5% +$42.1K 0.42% 33
2018
Q2
$714K Sell
20,741
-10
-0% -$342 0.34% 44
2018
Q1
$699K Sell
20,751
-101
-0.5% -$3.47K 0.33% 44
2017
Q4
$717K Sell
20,852
-76
-0.4% -$2.59K 0.34% 44
2017
Q3
$709K Sell
20,928
-124
-0.6% -$3.98K 0.36% 43
2017
Q2
$671K Buy
21,052
+47
+0.2% +$1.48K 0.36% 45
2017
Q1
$682K Sell
21,005
-1,130
-5% -$35.6K 0.39% 43
2016
Q4
$682K Sell
22,135
-1,116
-5% -$34.1K 0.43% 40
2016
Q3
$747K Buy
23,251
+1,104
+5% +$36.9K 0.46% 35
2016
Q2
$740K Buy
22,147
+22
+0.1% +$702 0.47% 35
2016
Q1
$622K Buy
22,125
+47
+0.2% +$1.34K 0.41% 38
2015
Q4
$676K Sell
22,078
-3,686
-14% -$116K 0.46% 36
2015
Q3
$768K Buy
25,764
+1,967
+8% +$63.1K 0.55% 33
2015
Q2
$757K Sell
23,797
-271
-1% -$8.83K 0.52% 38
2015
Q1
$794K Buy
24,068
+205
+0.9% +$6.52K 0.55% 31
2014
Q4
$705K Buy
23,863
+240
+1% +$6.88K 0.51% 34
2014
Q3
$663K Buy
23,623
+105
+0.4% +$2.95K 0.51% 33
2014
Q2
$662K Buy
23,518
+46
+0.2% +$1.31K 0.51% 32
2014
Q1
$715K Buy
23,472
+43
+0.2% +$1.28K 0.57% 28
2013
Q4
$681K Buy
23,429
+421
+2% +$12.3K 0.54% 30
2013
Q3
$627K Sell
23,008
-316
-1% -$8.6K 0.56% 29
2013
Q2
$620K Buy
+23,324
New +$644K 0.6% 26

Other funds holding PFE

Summit Asset Management's PFE Position: Q2 2026 in Review

Summit Asset Management reduced its Pfizer (PFE) stake by 0.8% in Q2 2026, selling an estimated $4K and leaving 18,916 shares worth $455K. The position accounts for 0.06% of the portfolio, ranked #118.

Summit Asset Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.44M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Summit Asset Management held 18,916 shares of Pfizer worth $455K as of Q2 2026.
  • Summit Asset Management sold 153 Pfizer shares in Q2 2026, an estimated $4K.
  • Pfizer made up 0.06% of Summit Asset Management's portfolio in Q2 2026, its #118 holding.
  • Summit Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Summit Asset Management's Pfizer position peaked at $1.44M in Q4 2021.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Summit Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.